探索KAT6作为乳腺癌的治疗点:精准医学的表观遗传方法
Cyril Roussel-Simonin1,2, Aranzazu Fernandez-Martinez3,4,5, Sophie Postel-Vinay3,4,6
1Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France. Cyril.roussel-simonin@gustaveroussy.fr.
NPJ breast cancer
|December 19, 2025
概括
氨酸乙转移酶6 (KAT6A/B) 是激素受体阳性乳腺癌的关键调节剂. 抑制KAT6A/B显示出克服治疗耐药性和改善患者结果的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 激素受体阳性 (HR+) 乳腺癌是女性癌症死亡的主要原因.
- 尽管有针对性的治疗方法取得了进展,但治疗耐药性仍然是一个重大挑战.
- 表观遗传失调,包括基因组乙化,与乳腺癌的进展和耐药性有关.
研究的目的:
- 审查氨酸乙转移酶6 (KAT6A/B) 在HR+乳腺癌中的作用.
- 突出KAT6A/B作为潜在的治疗点.
- 讨论KAT6抑制对克服治疗耐药性的影响.
主要方法:
- 对KAT6A/B功能和抑制的临床前证据的审查.
- 分析KAT6A/B在基因调节和瘤性途径中的分子机制.
- 探索针对乳腺癌的表观遗传药物开发的挑战和前景.
主要成果:
- KAT6A/B调节了组织素乙化,染色质结构和基因表达.
- 这些酶参与转录激活,染色质重塑和细胞衰老.
- 临床前研究支持KAT6抑制剂的治疗潜力.
结论:
- KAT6A/B是HR+乳腺癌的有希望的治疗点.
- 抑制KAT6可能是克服治疗耐药性的策略.
- 基于生物标志物的方法和组合疗法对于临床成功至关重要.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.0K
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.7K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
